Erratum to: Audit of acute Charcot’s disease in the UK: the CDUK study

Abstract

Unfortunately the references cited in the fourth paragraph of the Introduction were incorrect. The paragraph is printed below, with the corrected references highlighted in red. It is generally accepted that off-loading in a non-removable below-knee cast or cast-walker is an essential part of management [8, 9]. In addition, the use of pamidronate was shown in an open-label study to reduce skin temperature and bone turnover markers [12], the latter effect being subsequently confirmed in a randomised controlled trial (RCT) [13]. Another small RCT demonstrated that weekly treatment with alendronate also led to a significant reduction in bone turnover markers, associated with reduced discomfort [14]. Despite these observations, the long-term clinical benefit of non-removable off-loading or bisphosphonate therapy has not yet been clearly established. Diabetologia (2012) 55:862 DOI 10.1007/s00125-011-2420-1